ArticleFrontiers in oncology2020
S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Induction immunochemotherapy followed by concurrent chemoradiotherapy improves survival in unresectable esophageal cancer: a systematic review, meta-analysis, and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Nimotuzumab Combined With Concurrent Curative Radiotherapy and S-1 in 75 Years and Older Patients With Stage II-IVB Esophageal Squamous Cell Carcinoma: A Phase II Study.International journal of cancer · 2026Trial
- Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.JAMA network open · 2023Trial
- A machine learning approach for radiation pneumonitis prediction in elderly esophageal cancer patients by integrating baseline computed tomography radiomics, dosiomics, and clinical characteristics.Physics and imaging in radiation oncology · 2025Article
- Intensity modulated radiation therapy for elderly patients with esophageal cancer: Our experience.Biomolecules & biomedicine · 2023Article
- Induction Chemotherapy Followed by Chemoradiotherapy With or Without Consolidation Chemotherapy Versus Chemoradiotherapy Followed by Consolidation Chemotherapy for Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- Long-Term Results of a Phase 2 Study of Definitive Chemoradiation Therapy Using S-1 for Esophageal Squamous Cell Carcinoma Patients Who Were Elderly or With Serious Comorbidities.Frontiers in oncology · 2022Article
- Treatment Patterns and Outcomes of Elderly Patients With Potentially Curable Esophageal Cancer.Frontiers in oncology · 2022Article
- Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: A phase II clinical trial.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors at 9 institutions in 1 country.
Xin WangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiaolin GeDepartment of Radiation Oncology, Jiangsu Province Hospital (The First Affiliated Hospital With Nanjing Medical University), Nanjing, China.
Xiaomin WangDepartment of Radiation Oncology, Anyang Cancer Hospital, Anyang, China.
Wencheng ZhangDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Haiwen ZhouDepartment of Radiation Oncology, Anyang Cancer Hospital, Anyang, China.
Yu LinDepartment of Radiation Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.
Shuai QieDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Miaomiao HuDepartment of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
Wei WangDepartment of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
Ke LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qingsong PangDepartment of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Minghe LiDepartment of Radiation Oncology, Anyang Cancer Hospital, Anyang, China.
Junqiang ChenDepartment of Radiation Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, China.
Miaoling LiuDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Kaixian ZhangDepartment of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
Ling LiDepartment of Oncology, Tengzhou Central People's Hospital, Tengzhou, China.
Yonggang ShiDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Wei DengKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Chen LiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wenjie NiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xiao ChangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Weiming HanDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Lei DengDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wenqing WangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jun LiangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Nan BiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Tao ZhangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wenyang LiuDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jianyang WangDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yirui ZhaiDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Qinfu FengDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Dongfu ChenDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Zongmei ZhouDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yidian ZhaoDepartment of Radiation Oncology, Anyang Cancer Hospital, Anyang, China.
Xinchen SunDepartment of Radiation Oncology, Jiangsu Province Hospital (The First Affiliated Hospital With Nanjing Medical University), Nanjing, China.
Zefen XiaoDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNTengzhou Central People's Hospital · CNAnyang Tumor Hospital · CNAffiliated Hospital of Hebei University · CNFirst Affiliated Hospital of Zhengzhou University · CNFujian Provincial Cancer Hospital · CNNanjing Medical University · CNTianjin Medical University Cancer Institute and Hospital · CNPeking University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
adjuvantagedchemoradiotherapychemotherapyesophageal neoplasmsgeriatric assessmentintensity-modulatedradiotherapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.